EUCTR2008-004578-42-CZ
Active, not recruiting
Phase 1
An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium - The Imaging Sub-study for the Fracture Trial
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Merck & Co., Inc.
- Enrollment
- 164
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Participant is already enrolled in Protocol 018\.
- •2\.Participant is willing to undergo all QCT and DXA imaging procedures and biomarker assessments.
- •3\. Participant's body habitus allows for QCT scanning (i.e. Body Mass Index (BMI) is \= 35 kg/m2\).
- •4\.Participant has two hips that are evaluable by DXA and QCT (e.g., contain no hardware from orthopedic procedures). Note: Surgical clips are acceptable.5\.Participant has a spinal anatomy suitable for DXA and QCT of the lumbar spine. (e.g. does not have significant scoliosis, bone deformity, hardware or sequelae of orthopedic procedures. Note: Surgical clips are acceptable.) For DXA, at least 2 vertebrae from L1\-L4 must be evaluable and for QCT, at least 2 vertebrae from T12\-L3 must be evaluable.
- •6\. Participant understands the study procedures and the risks involved with the study and voluntarily agrees to participate by giving written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) no
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
Exclusion Criteria
- •1\. Participant has a history of tremors, Parkinson's disease, multiple sclerosis or other diseases that cause persistent tremors.
- •2\.Participant is unlikely to adhere to the study procedures or keep appointments, or is planning to relocate during the study.
- •3\. Participant baseline QCT imaging scan, of the hip or spine, is of insufficient quality, as confirmed by the central imaging vendor.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium - The Imaging Sub-study for the Fracture TrialPostmenopausal OsteoporosisMedDRA version: 9.1Level: LLTClassification code 10017082Term: Fracture due to osteoporosisMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2008-004578-42-DKMerck & Co. Inc.400
Active, not recruiting
Not Applicable
An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium - The Imaging Sub-study for the Fracture TrialEUCTR2008-004578-42-EEMerck & Co., Inc.350
Recruiting
Phase 3
A clinical trial to compare toxicity reduction between image guided intensity modulated radiotherapy (IG-IMRT) and conventional radiotherapy in Cancer Cervix (PARCER) patients.Health Condition 1: null- Cervical cancerCTRI/2012/12/003249Tata Memorial Centre240
Active, not recruiting
Phase 1
A trial to learn if dupilumab is safe for and helps adult and adolescent participants with eosinophilic gastritis with or without eosinophilic duodenitisCTIS2022-500795-62-00Regeneron Pharmaceuticals Inc.285
Not yet recruiting
Phase 2
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic DuodenitisJPRN-jRCT2031230539Shabbir Arsalan Q.32